Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease | Zendy

Elisabetta Patorno | Zendy; Phyo T. Htoo | Zendy; Robert J. Glynn | Zendy; Sebastian Schneeweiß | Zendy; Deborah J. Wexler | Zendy; Ajinkya Pawar | Zendy; Lily G. Bessette | Zendy; Kristyn Chin | Zendy; Brendan M. Everett | Zendy; Seoyoung C. Kim | Zendy

Open Access

Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

Author(s) -

Elisabetta Patorno,

Phyo T. Htoo,

Robert J. Glynn,

Sebastian Schneeweiß,

Deborah J. Wexler,

Ajinkya Pawar,

Lily G. Bessette,

Kristyn Chin,

Brendan M. Everett,

Seoyoung C. Kim

Publication year - 2021

Publication title -

annals of internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.839

H-Index - 390

eISSN - 1539-3704

pISSN - 0003-4819

DOI - 10.7326/m21-0893

Subject(s) - medicine , hazard ratio , myocardial infarction , type 2 diabetes , stroke (engine) , diabetes mellitus , population , placebo , heart failure , glucagon like peptide 1 receptor , endocrinology , confidence interval , receptor , mechanical engineering , alternative medicine , environmental health , pathology , engineering , agonist

Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-controlled trials of patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research